AstraZeneca CEO: Match 'Chinese Speed' or Lose
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pascal Soriot urged AstraZeneca to operate at 'Chinese speed' in drug innovation, warning western pharma faces the same fate as automakers who ceded electric vehicles to Chinese rivals.
- AstraZeneca reported first-half 2026 revenues of £30.7bn, up 6% year-on-year at constant exchange rates.
- AstraZeneca reaffirmed confidence in hitting its 2030 annual sales target of $80bn, up from $59bn last year, calling its drug pipeline 'unmatched'.
- Wainua, AstraZeneca's major heart disease drug prospect, suffered a surprise clinical trial failure earlier this month; Soriot said the company must 'accept to fail some of the time.'
- Soriot dismissed fears of AI-driven job losses as 'a bit of a fake story,' saying AI tools make him 'faster and smarter' in drug development work.
- Chinese pharmaceutical companies are investing heavily in antibody drug conjugates and cell therapy, technologies Soriot flagged as the critical battlegrounds.
- AstraZeneca plans to engage with the UK government under its new leader Andy Burnham over a US-UK drug pricing deal, struck under tariff pressure from Trump, that could cost the NHS billions and has been linked to a projected 229,000 excess deaths in England.
Why it matters: AstraZeneca's path to its $80bn 2030 sales target depends on out-innovating Chinese rivals accelerating in antibody drug conjugates and cell therapy. With first-half revenue already at £30.7bn (up 6%), the company has financial runway — but Wainua's clinical trial failure shows the pipeline risk that comes with racing at 'Chinese speed.'
